Francisca Castillo

Francisca Castillo

Auto-generated profile, based on publicly available information

Francisca Castillo

Center for Molecular Medicine, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2019 in Journal of Periodontal Research
Verified
Journal Article
Closed access
PDF file
GMGustavo Monasterio
Gustavo Monasterio
VBVictoria Budini
Victoria Budini
BFBaltasar Fernández
Baltasar Fernández
FCFrancisca Castillo
Francisca Castillo
CPCarolina isabel Rojas Pérez
Carolina isabel Rojas Pérez
Rolando VernalRolando Vernal
Rolando Vernal


28 September 2022 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
KIKatrine Ingelshed
Katrine Ingelshed
DSDiana Spiegelberg
Diana Spiegelberg
PKPavitra Kannan
Pavitra Kannan
LPLinnéa Påvénius
Linnéa Påvénius
JHJessica Hacheney
Jessica Hacheney
SSSaikiran Sedimbi
Saikiran Sedimbi
The tumor suppressor protein p53 is mutated in close to 50% of human tumors and is dysregulated in many others, for instance by silencing or loss of p14ARF. Under steady-state conditions, the two E3 ligases MDM2/MDM4 interact with and inhibit the transcriptional activity of p53. Inhibition of p53–MDM2/4 interaction to reactivate p53 in tumors with wild-type (WT) p53 has therefore been considered a therapeutic strategy. Moreover, studies indicate that p53 reactivation may synergize with radiation and increase tumor immunogenicity. In vivo studies of most MDM2 inhibitors have utilized immunodeficient xenograft mouse models, preventing detailed studies of action of these molecules on the immune response. The mouse melanoma cell line B16-F10 carries functional, WT p53 but does not express the MDM2 regulator p19ARF. In this study, we tested a p53-MDM2 protein–protein interaction inhibitor, the small molecule Navtemadlin, which is currently being tested in phase II clinical trials. Using mass spectrometry–based proteomics and imaging flow cytometry, we identified specific protein expression patterns following Navtemadlin treatment of B16-F10 melanoma cells compared with their p53 CRISPR-inactivated control cells. In vitro, Navtemadlin induced a significant, p53-dependent, growth arrest but little apoptosis in B16-F10 cells. When combined with radiotherapy, Navtemadlin showed synergistic effects and increased apoptosis. In vivo, Navtemadlin treatment significantly reduced the growth of B16-F10 melanoma cells implanted in C57Bl/6 mice. Our data highlight the utility of a syngeneic B16-F10 p53+/+ mouse melanoma model for assessing existing and novel p53-MDM2/MDM4 inhibitors and in identifying new combination therapies that can efficiently eliminate tumors in vivo.Significance: The MDM2 inhibitor Navtemadlin arrests mouse tumor growth and potentiates radiotherapy. Our results support a threshold model for apoptosis induction that requires a high, prolonged p53 signaling for cancer cells to become apoptotic.

5 February 2021 in Clinical Oral Investigations
Verified
Journal Article
Closed access
PDF file
FCFrancisca Castillo
Francisca Castillo
GMGustavo Monasterio
Gustavo Monasterio
JIJuan Pablo Ibarra
Juan Pablo Ibarra
JGJosé Guevara
José Guevara
ECEmilio A Cafferata
Emilio A Cafferata
Rolando VernalRolando Vernal
Rolando Vernal

28 February 2018
Verified
Book Chapter
Open access
PDF file
GMGustavo Monasterio
Gustavo Monasterio
FCFrancisca Castillo
Francisca Castillo
DBDaniel Betancur
Daniel Betancur
AHArnoldo Hernández
Arnoldo Hernández
GFGuillermo Flores
Guillermo Flores
Rolando VernalRolando Vernal
Rolando Vernal
Osteoarthritis is a degenerative disease affecting the TMJ. It is the most common TMJ disorder and shows a higher prevalence in women and older people. TMJ osteoarthritis (TMJ-OA) is characterized by variable degrees of inflammation, destruction of the articular cartilage, and sub-chondral bone resorption. In this context, diverse pro-inflammatory cytokines, chemokines, enzymes, and bone-resorptive associated factors have been considered as possible markers of active TMJ-OA. The molecular balance is determinant not only for initiation and progression, but also for the clinical expression of the disease. Recent advances in the biochemical analysis of synovial fluid from affected patients have provided new insights into the patho-physiology of the TMJ-OA; however, its molecular pathogenesis still remains unclear. Recently, a Th1 and Th17-dominated immune response has been associated with the inflammatory and destructive events characteristic of TMJ-OA and, in particular, the Th17 lymphocyte pathway has a pivotal role in the increased production of RANKL, which is involved in osteoclast activation and subsequent sub-chondral bone resorption. Understanding the TMJ physiology and pathogenesis of the TMJ-OA, together with the key molecular determinants of the TMJ tissue destruction, will enable the development of new chair-side point of care diagnostics and more conservative treatment modalities with minimal complications.

4 April 2023
Verified
Other
Open access
KIKatrine Ingelshed
Katrine Ingelshed
DSDiana Spiegelberg
Diana Spiegelberg
PKPavitra Kannan
Pavitra Kannan
LPLinnéa Påvénius
Linnéa Påvénius
JHJessica Hacheney
Jessica Hacheney
SSSaikiran Sedimbi
Saikiran Sedimbi
Navtemadlin treatment does not affect tumor infiltrating myeloid cells.